Inhibitory effects of prostaglandin E2 on collagen synthesis and cell proliferation in human stellate cells from pancreatic head adenocarcinoma

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Pomianowska, Ewa ^a,b   Sandnes, Dagny ^a   Grzyb, Krzysztof ^b   Schjølberg, Aasa R ^a   Aasrum, Monica ^a   Tveteraas, Ingun H ^a   Tjomsland, Vegard ^a,b   Christoffersen, Thoralf ^a   Gladhaug, Ivar P ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Collagen synthesis; Cyclic AMP; DNA synthesis; Pancreatic stellate cells; Prostaglandin E2

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; C PEPTIDE; COLLAGEN; COLLAGEN 1A1; CYCLIC AMP; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR; FORSKOLIN; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E2; THROMBIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG;

ADENOCARCINOMA CELL LINE; ADULT; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BIOACCUMULATION; CELL ACTIVATION; CELL ISOLATION; COCULTURE; COLLAGEN SYNTHESIS INHIBITION; CONTROLLED STUDY; CYSTIC FIBROSIS; DNA SYNTHESIS; DNA SYNTHESIS INHIBITION; ENZYME IMMUNOASSAY; ENZYME PHOSPHORYLATION; ENZYME SYNTHESIS; FIBROGENESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; PANCREAS ADENOCARCINOMA; PANCREATIC STELLATE CELL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SYNTHESIS INHIBITION; RADIOIMMUNOASSAY; REAL TIME POLYMERASE CHAIN REACTION; STROMA CELL; BIOSYNTHESIS; CELL CULTURE; DNA REPLICATION; DRUG EFFECTS; GENE EXPRESSION; GENETICS; METABOLISM; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; CELLS, CULTURED; COCULTURE TECHNIQUES; COLLAGEN; CYCLOOXYGENASE 2; DINOPROSTONE; DNA REPLICATION; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; PANCREATIC NEOPLASMS; PANCREATIC STELLATE CELLS;

EID: 84903989489     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-413     Document Type: Article

References (64)

1. Krejs GJ. Pancreatic cancer: epidemiology and risk factors. Dig Dis 2010, 28(2):355-358.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
3. Hidalgo M. Pancreatic cancer. N Engl J Med 2010, 362(17):1605-1617.
4. Chu GC, Kimmelman AC, Hezel AF, DePinho RA. Stromal biology of pancreatic cancer. J Cell Biochem 2007, 101(4):887-907.
5. Apte MV, Park S, Phillips PA, Santucci N, Goldstein D, Kumar RK, Ramm GA, Buchler M, Friess H, McCarroll JA, Keogh G, Merrett N, Pirola R, Wilson JS. Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas 2004, 29(3):179-187.
6. Apte MV, Pirola RC, Wilson JS. Pancreatic stellate cells: a starring role in normal and diseased pancreas. Front Physiol 2012, 3:344.
7. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Ruckert F, Grutzmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M, et al. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324(5933):1457-1461.
8. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, Torigian DA, O'Dwyer PJ, Vonderheide RH. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331(6024):1612-1616.
9. Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, Feig C, Nakagawa T, Caldwell ME, Zecchini HI, Lolkema MP, Jiang P, Kultti A, Thompson CB, Maneval DC, Jodrell DI, Frost GI, Shepard HM, Skepper JN, Tuveson DA. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 2013, 62(1):112-120.
10. Vonlaufen A, Joshi S, Qu C, Phillips PA, Xu Z, Parker NR, Toi CS, Pirola RC, Wilson JS, Goldstein D, Apte MV. Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res 2008, 68(7):2085-2093.
11. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 2010, 10(3):181-193.
12. Okami J, Yamamoto H, Fujiwara Y, Tsujie M, Kondo M, Noura S, Oshima S, Nagano H, Dono K, Umeshita K, Ishikawa O, Sakon M, Matsuura N, Nakamori S, Monden M. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res 1999, 5(8):2018-2024.
13. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, Soslow RA, Masferrer JL, Woerner BM, Koki AT, Fahey TJ. Cyclooxygenase-2 expression is Up-regulated in human pancreatic cancer. Cancer Res 1999, 59(5):987-990.
14. Yip-Schneider MT, Barnard DS, Billings SD, Cheng L, Heilman DK, Lin A, Marshall SJ, Crowell PL, Marshall MS, Sweeney CJ. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 2000, 21(2):139-146.
15. Juuti A, Louhimo J, Nordling S, Ristimaki A, Haglund C. Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J Clin Pathol 2006, 59(4):382-386.
16. Matsubayashi H, Infante JR, Winter J, Klein AP, Schulick R, Hruban R, Visvanathan K, Goggins M. Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer. Cancer Biol Ther 2007, 6(10):1569-1575.
17. Muller-Decker K, Furstenberger G, Annan N, Kucher D, Pohl-Arnold A, Steinbauer B, Esposito I, Chiblak S, Friess H, Schirmacher P, Berger I. Preinvasive duct-derived neoplasms in pancreas of keratin 5-promoter cyclooxygenase-2 transgenic mice. Gastroenterology 2006, 130(7):2165-2178.
18. Colby JK, Klein RD, McArthur MJ, Conti CJ, Kiguchi K, Kawamoto T, Riggs PK, Pavone AI, Sawicki J, Fischer SM. Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression. Neoplasia 2008, 10(8):782-796.
19. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001, 41:661-690.
20. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem 2007, 282(16):11613-11617.
21. Ji R, Chou CL, Xu W, Chen XB, Woodward DF, Regan JW. EP1 prostanoid receptor coupling to G I/o Up-regulates the expression of hypoxia-inducible factor-1 alpha through activation of a phosphoinositide-3 kinase signaling pathway. Mol Pharmacol 2010, 77(6):1025-1036.
22. Hirata T, Narumiya S. Prostanoid receptors. Chem Rev 2011, 111(10):6209-6230.
23. Yokoyama U, Patel HH, Lai NC, Aroonsakool N, Roth DM, Insel PA. The cyclic AMP effector epac integrates Pro- and anti-fibrotic signals. Proc Natl Acad Sci U S A 2008, 105(17):6386-6391.
24. Bozyk PD, Moore BB. Prostaglandin E2 and the pathogenesis of pulmonary fibrosis. Am J Respir Cell Mol Biol 2011, 45(3):445-452.
25. Insel PA, Murray F, Yokoyama U, Romano S, Yun H, Brown L, Snead A, Lu D, Aroonsakool N. CAMP and Epac in the regulation of tissue fibrosis. Br J Pharmacol 2012, 166(2):447-456.
26. White KE, Ding Q, Moore BB, Peters-Golden M, Ware LB, Matthay MA, Olman MA. Prostaglandin E2 mediates IL-1beta-related fibroblast mitogenic effects in acute lung injury through differential utilization of prostanoid receptors. J Immunol 2008, 180(1):637-646.
27. Watanabe T, Satoh H, Togoh M, Taniguchi S, Hashimoto Y, Kurokawa K. Positive and negative regulation of cell proliferation through prostaglandin receptors in NIH-3 T3 cells. J Cell Physiol 1996, 169(2):401-409.
28. Oga T, Matsuoka T, Yao C, Nonomura K, Kitaoka S, Sakata D, Kita Y, Tanizawa K, Taguchi Y, Chin K, Mishima M, Shimizu T, Narumiya S. Prostaglandin F (2alpha) receptor signaling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-beta. Nat Med 2009, 15(12):1426-1430.
29. Harding P, LaPointe MC. Prostaglandin E2 increases cardiac fibroblast proliferation and increases cyclin D expression Via EP1 receptor. Prostaglandins Leukot Essent Fatty Acids 2011, 84(5-6):147-152.
30. Hui AY, Dannenberg AJ, Sung JJ, Subbaramaiah K, Du B, Olinga P, Friedman SL. Prostaglandin E2 inhibits transforming growth factor beta 1-mediated induction of collagen alpha 1(I) in hepatic stellate cells. J Hepatol 2004, 41(2):251-258.
31. Mallat A, Gallois C, Tao J, Habib A, Maclouf J, Mavier P, Preaux AM, Lotersztajn S. Platelet-derived growth factor-BB and thrombin generate positive and negative signals for human hepatic stellate cell proliferation. Role of a prostaglandin/cyclic AMP pathway and cross-talk with endothelin receptors. J Biol Chem 1998, 273(42):27300-27305.
32. Koide S, Kobayashi Y, Oki Y, Nakamura H. Prostaglandin E2 inhibits platelet-derived growth factor-stimulated cell proliferation through a prostaglandin E receptor EP2 subtype in Rat hepatic stellate cells. Dig Dis Sci 2004, 49(9):1394-1400.
33. Bachem MG, Schneider E, Gross H, Weidenbach H, Schmid RM, Menke A, Siech M, Beger H, Grunert A, Adler G. Identification, culture, and characterization of pancreatic stellate cells in rats and humans. Gastroenterology 1998, 115(2):421-432.
34. Refsnes M, Thoresen GH, Dajani OF, Christoffersen T. Stimulation of hepatocyte DNA synthesis by prostaglandin E2 and prostaglandin F2 alpha: additivity with the effect of norepinephrine, and synergism with epidermal growth factor. J Cell Physiol 1994, 159(1):35-40.
35. Jaster R, Hilgendorf I, Fitzner B, Brock P, Sparmann G, Emmrich J, Liebe S. Regulation of pancreatic stellate cell function in vitro: biological and molecular effects of all-trans retinoic acid. Biochem Pharmacol 2003, 66(4):633-641.
36. Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL. Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinforma 2012, 13:134.
37. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-delta delta C (T)) method. Methods 2001, 25(4):402-408.
38. Skomedal T, Grynne B, Osnes JB, Sjetnan AE, Oye I. A radioimmunoassay for cyclic AMP (CAMP) obtained by acetylation of both unlabeled and labeled (3H-CAMP) ligand, or of unlabeled ligand only. Acta Pharmacol Toxicol (Copenh) 1980, 46(3):200-204.
39. Sato N, Maehara N, Goggins M. Gene expression profiling of tumor-stromal interactions between pancreatic cancer cells and stromal fibroblasts. Cancer Res 2004, 64(19):6950-6956.
40. Charo C, Holla V, Arumugam T, Hwang R, Yang P, Dubois RN, Menter DG, Logsdon CD, Ramachandran V. Prostaglandin E2 regulates pancreatic stellate cell activity Via the EP4 receptor. Pancreas 2013, 42(3):467-474.
41. Huang S, Wettlaufer SH, Hogaboam C, Aronoff DM, Peters-Golden M. Prostaglandin E (2) inhibits collagen expression and proliferation in patient-derived normal lung fibroblasts Via E prostanoid 2 receptor and CAMP signaling. Am J Physiol Lung Cell Mol Physiol 2007, 292(2):L405-L413.
42. Seamon KB, Padgett W, Daly JW. Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proc Natl Acad Sci U S A 1981, 78(6):3363-3367.
43. Machwate M, Harada S, Leu CT, Seedor G, Labelle M, Gallant M, Hutchins S, Lachance N, Sawyer N, Slipetz D, Metters KM, Rodan SB, Young R, Rodan GA. Prostaglandin receptor EP (4) mediates the bone anabolic effects of PGE(2). Mol Pharmacol 2001, 60(1):36-41.
44. Bachem MG, Schunemann M, Ramadani M, Siech M, Beger H, Buck A, Zhou S, Schmid-Kotsas A, Adler G. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 2005, 12847(4):907-921.
45. Luttenberger T, Schmid-Kotsas A, Menke A, Siech M, Beger H, Adler G, Grunert A, Bachem MG. Platelet-derived growth factors stimulate proliferation and extracellular matrix synthesis of pancreatic stellate cells: implications in pathogenesis of pancreas fibrosis. Lab Invest 2000, 80(1):47-55.
46. Menke A, Adler G. TGFbeta-induced fibrogenesis of the pancreas. Int J Gastrointest Cancer 2002, 31(1-3):41-46.
47. Wilborn J, Crofford LJ, Burdick MD, Kunkel SL, Strieter RM, Peters-Golden M. Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2. J Clin Invest 1995, 95(4):1861-1868.
48. Keerthisingam CB, Jenkins RG, Harrison NK, Hernandez-Rodriguez NA, Booth H, Laurent GJ, Hart SL, Foster ML, McAnulty RJ. Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice. Am J Pathol 2001, 158(4):1411-1422.
49. Handler JA, Danilowicz RM, Eling TE. Mitogenic signaling by epidermal growth factor (EGF), but Not platelet-derived growth factor, requires arachidonic acid metabolism in BALB/c 3 T3 cells. Modulation of EGF-dependent C-Myc expression by prostaglandins. J Biol Chem 1990, 265(7):3669-3673.
50. Castano E, Bartrons R, Gil J. Inhibition of cyclooxygenase-2 decreases DNA synthesis induced by platelet-derived growth factor in Swiss 3 T3 fibroblasts. J Pharmacol Exp Ther 2000, 293(2):509-513.
51. Yoshida S, Ujiki M, Ding XZ, Pelham C, Talamonti MS, Bell RH, Denham W, Adrian TE. Pancreatic stellate cells (PSCs) express cyclooxygenase-2 (COX-2) and pancreatic cancer stimulates COX-2 in PSCs. Mol Cancer 2005, 4(1):27.
52. Smith ML, Hawcroft G, Hull MA. The effect of Non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. Eur J Cancer 2000, 36(5):664-674.
53. Denkert C, Furstenberg A, Daniel PT, Koch I, Kobel M, Weichert W, Siegert A, Hauptmann S. Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but Not by COX-2-specific RNA interference. Oncogene 2003, 22(54):8653-8661.
54. Elder DJ, Halton DE, Hague A, Paraskeva C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin Cancer Res 1997, 3(10):1679-1683.
55. Black SA, Palamakumbura AH, Stan M, Trackman PC. Tissue-specific mechanisms for CCN2/CTGF persistence in fibrotic gingiva: interactions between CAMP and MAPK signaling pathways, and prostaglandin E2-EP3 receptor mediated activation of the C-JUN N-terminal kinase. J Biol Chem 2007, 282(21):15416-15429.
56. Kokawa A, Kondo H, Gotoda T, Ono H, Saito D, Nakadaira S, Kosuge T, Yoshida S. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer 2001, 91(2):333-338.
57. Kong G, Kim EK, Kim WS, Lee KT, Lee YW, Lee JK, Paik SW, Rhee JC. Role of cyclooxygenase-2 and inducible nitric oxide synthase in pancreatic cancer. J Gastroenterol Hepatol 2002, 17(8):914-921.
58. Koshiba T, Hosotani R, Miyamoto Y, Wada M, Lee JU, Fujimoto K, Tsuji S, Nakajima S, Doi R, Imamura M. Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors. Int J Pancreatol 1999, 26(2):69-76.
59. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 1999, 59(17):4356-4362.
60. Schlosser W, Schlosser S, Ramadani M, Gansauge F, Gansauge S, Beger HG. Cyclooxygenase-2 is overexpressed in chronic pancreatitis. Pancreas 2002, 25(1):26-30.
61. Saukkonen K, Nieminen O, Van RB, Vilkki S, Harkonen M, Juhola M, Mecklin JP, Sipponen P, Ristimaki A. Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma. Clin Cancer Res 2001, 7(7):1923-1931.
62. Vonlaufen A, Phillips PA, Yang L, Xu Z, Fiala-Beer E, Zhang X, Pirola RC, Wilson JS, Apte MV. Isolation of quiescent human pancreatic stellate cells: a promising in vitro tool for studies of human pancreatic stellate cell biology. Pancreatology 2010, 10(4):434-443.
63. Aoki H, Ohnishi H, Hama K, Shinozaki S, Kita H, Osawa H, Yamamoto H, Sato K, Tamada K, Sugano K. Cyclooxygenase-2 is required for activated pancreatic stellate cells to respond to proinflammatory cytokines. Am J Physiol Cell Physiol 2007, 292(1):C259-C268.
64. Xu D, Matsuo Y, Ma J, Koide S, Ochi N, Yasuda A, Funahashi H, Okada Y, Takeyama H. Cancer cell-derived IL-1alpha promotes HGF secretion by stromal cells and enhances metastatic potential in pancreatic cancer cells. J Surg Oncol 2010, 102(5):469-477.